ATE429233T1 - Verwendung mindestens einer glycoinhibitor- substanz gegen infektionskrankheiten - Google Patents

Verwendung mindestens einer glycoinhibitor- substanz gegen infektionskrankheiten

Info

Publication number
ATE429233T1
ATE429233T1 AT02751212T AT02751212T ATE429233T1 AT E429233 T1 ATE429233 T1 AT E429233T1 AT 02751212 T AT02751212 T AT 02751212T AT 02751212 T AT02751212 T AT 02751212T AT E429233 T1 ATE429233 T1 AT E429233T1
Authority
AT
Austria
Prior art keywords
glycoinhibitor
infectious diseases
against infectious
substance against
neutral glycan
Prior art date
Application number
AT02751212T
Other languages
English (en)
Inventor
Jari Natunen
Halina Miller-Podraza
Susann Teneberg
Jonas Angstroem
Karl-Anders Karlsson
Original Assignee
Glykos Finland Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20011403A external-priority patent/FI20011403A7/fi
Priority claimed from FI20011402A external-priority patent/FI20011402A7/fi
Application filed by Glykos Finland Oy filed Critical Glykos Finland Oy
Application granted granted Critical
Publication of ATE429233T1 publication Critical patent/ATE429233T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Saccharide Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
AT02751212T 2001-06-29 2002-06-28 Verwendung mindestens einer glycoinhibitor- substanz gegen infektionskrankheiten ATE429233T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20011403A FI20011403A7 (fi) 2001-06-29 2001-06-29 Menetelmä ja koostumukset vatsan sairauksien hoitoon
FI20011402A FI20011402A7 (fi) 2001-06-29 2001-06-29 Lääkkeet ja hoitotavat patogeenejä vastaan
PCT/FI2002/000574 WO2003002127A1 (en) 2001-06-29 2002-06-28 Use of at least one glycoinhibitor substance

Publications (1)

Publication Number Publication Date
ATE429233T1 true ATE429233T1 (de) 2009-05-15

Family

ID=26161191

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02751212T ATE429233T1 (de) 2001-06-29 2002-06-28 Verwendung mindestens einer glycoinhibitor- substanz gegen infektionskrankheiten

Country Status (7)

Country Link
US (1) US20040176320A1 (de)
EP (1) EP1411952B1 (de)
JP (1) JP2005504017A (de)
AT (1) ATE429233T1 (de)
AU (1) AU2002352531A1 (de)
DE (1) DE60232077D1 (de)
WO (1) WO2003002127A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004537976A (ja) 2001-03-15 2004-12-24 インターナショナル バイオイムン システムズ，インコーポレーテッド 膵癌のモノクローナル抗体治療
DK1531832T3 (da) * 2002-06-28 2009-07-27 Glykos Finland Oy Terapeutiske sammensætninger til anvendelse ved profylakse eller behandling af diarré
PT1675601E (pt) † 2003-10-13 2009-08-31 Nestec Sa Moderação do efeito de endotoxinas
WO2007036041A1 (en) * 2005-09-28 2007-04-05 Suleiman Igdoura Sialidase inhibitors for the treatment of cardiovascular disease
JP5035787B2 (ja) * 2005-10-04 2012-09-26 焼津水産化学工業株式会社 α−１、４結合型Ｎ−アセチルグルコサミン含有Ｏ−グリカン型糖鎖の分泌促進剤並びにこれを含有するヘリコバクターピロリ菌を原因とする病態の治療予防剤
EA021255B1 (ru) 2006-08-28 2015-05-29 Киова Хакко Кирин Ко., Лимитед Антагонистические моноклональные антитела человека, специфичные в отношении light человека
JP5014018B2 (ja) * 2006-10-18 2012-08-29 旭化成ケミカルズ株式会社 ピロリ菌の抑制剤または静菌剤
CA2702577A1 (en) 2007-10-15 2009-04-23 Jbs United, Inc. Method for increasing performance of offspring
EP2060257A1 (de) * 2007-11-08 2009-05-20 Nestec S.A. Vorbeugung und Behandlung von Sekundärinfektionen nach Virusinfektion
PT2265135T (pt) * 2008-03-14 2018-02-21 Nestec Sa Mistura simbiótica
EP2282648A4 (de) * 2008-06-09 2011-09-21 Temple Inland Präbiotische zusammensetzungen sowie herstellungs- und verwendungsverfahren dafür
GB0817908D0 (en) 2008-10-01 2008-11-05 Univ Ghent Blood group a/b/h determinant on type 1 core glycosphinglipids chain as recognition point for the fedf protein of f18-fimbriated enterotoxigenic
US9678005B1 (en) * 2008-12-03 2017-06-13 Arizona Board Of Regents On Behalf Of The University Of Arizona Devices and methods for detection of microorganisms
US8785402B2 (en) * 2009-07-31 2014-07-22 Academia Sinica Compositions and assays for treatment and diagnosis of helicobacter pylori infection and conditions
US8828970B2 (en) 2009-08-27 2014-09-09 Georgia-Pacific Wood Products Llc Methods of making and using a ruminant gas reduction composition
EP2509453A4 (de) 2009-12-08 2013-11-20 Tin Inc D B A Temple Inland Nährstoffzusammensetzung sowie verfahren zu ihrer herstellung und verwendung
AU2011210756B2 (en) * 2010-01-28 2016-11-03 Horizon Orphan Llc Method For Treating Liver Disorders With Receptor Associated Protein (RAP) Peptide-Fucosidase Inhibitor Conjugates
PL2549994T3 (pl) 2010-03-25 2016-06-30 Taihua Shouyue Hong Kong International Co Ltd Zastosowanie D-fagominy jako inhibitora przylegania bakterii do komórek nabłonka
WO2015123433A2 (en) * 2014-02-12 2015-08-20 Goddard Labs, Inc. Rapid detection of human pathogens in plant material or water
CA2940579A1 (en) 2014-03-13 2015-09-17 Universitaet Basel Carbohydrate ligands that bind to igm antibodies against myelin-associated glycoprotein
KR101613964B1 (ko) 2014-05-20 2016-04-21 농업회사법인 주식회사 생명의나무 글라이코매크로펩타이드 효소분해물을 유효성분으로 하는 헬리코박터 파이로리 감염 예방 또는 치료용 조성물
US11091591B2 (en) 2015-09-16 2021-08-17 Universität Basel Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids
BR112018012821B1 (pt) * 2015-12-22 2022-02-22 Universidad Nacional De Colombia Glicoinibidor que inibe a adesão da bactéria streptococcus que afeta o trato digestivo do peixe
EP3184536A1 (de) * 2015-12-22 2017-06-28 Westfälische Wilhelms-Universität Münster Oligosaccharidzusammensetzung zum binden an lectine
WO2019243672A1 (en) * 2018-06-19 2019-12-26 Glykos Biomedical Oy Conjugate

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK17885D0 (da) * 1985-01-14 1985-01-14 Karlsson Karl Anders Antiviralt middel
US5217715A (en) * 1988-08-01 1993-06-08 The United States Of America As Represented By The Department Of Health And Human Services Carbohydrate receptor for bacteria and method for use thereof
US5242800A (en) * 1990-01-30 1993-09-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Receptor for pathogenic fungi
MX9304638A (es) * 1992-07-31 1994-05-31 Neose Pharm Inc Composicion para tratar e inhibir las ulceras gastricas y duodenales.
EP0601417A3 (de) * 1992-12-11 1998-07-01 Hoechst Aktiengesellschaft Physiologisch verträglicher und physiologisch abbaubarer, Kohlenhydratrezeptorblocker auf Polymerbasis, ein Verfahren zu seiner Herstellung und seine Verwendung
HU9502497D0 (en) * 1993-02-26 1995-10-30 Normark Use of oligosaccharide glycosides as inhibitors of bacterial adherence
DE4408248A1 (de) * 1994-03-11 1995-09-14 Hoechst Ag Physiologisch verträgliche und physiologisch abbaubare Kohlenhydrat-Mimetika, ein Verfahren zur Herstellung und ihre Verwendung
US5665561A (en) * 1994-06-06 1997-09-09 The Rockefeller University Modulators of pneumococcal adherence to pulmonary and vascular cells and diagnostic and therapeutic applications
US5641760A (en) * 1994-06-17 1997-06-24 Pence, Inc. Method of treating candida infection
AU710576B2 (en) * 1996-05-03 1999-09-23 Neose Technologies, Inc. Bismuth salt of sialyloligosaccharide and a method for treating and inhibiting gastric and duodenal ulcers with same
SE9901007D0 (sv) * 1999-03-19 1999-03-19 Thomas Boren Use of fucosylated sialylated N-acetyl lactosamin carbohydrate structures for inhibition of bacterial adherence
US6664235B1 (en) * 1999-08-20 2003-12-16 Riken Medicaments comprising sialic acid derivatives as active ingredients
SE9904581D0 (sv) * 1999-12-15 1999-12-15 A & Science Invest Ab A novel helicobacter pylori-binding substance and use thereof

Also Published As

Publication number Publication date
WO2003002127A1 (en) 2003-01-09
JP2005504017A (ja) 2005-02-10
AU2002352531A1 (en) 2003-03-03
DE60232077D1 (de) 2009-06-04
EP1411952B1 (de) 2009-04-22
US20040176320A1 (en) 2004-09-09
EP1411952A1 (de) 2004-04-28

Similar Documents

Publication Publication Date Title
DE60232077D1 (de) Verwendung mindestens einer glycoinhibitor-substanz gegen infektionskrankheiten
BR0015992A (pt) Compostos, utilização dos mesmos, e, associações terapêuticas
BR0313371A (pt) Composto, uso de um composto e método de tratamento de doença
BR9812381A (pt) Peptopiranosilnucleosìdeo, seu preparo e uso
PT1333887E (pt) Metodo de tratamento de desordens musculares
NO20073831L (no) Medikamenter for behandling eller forebygging av fibrotiske sykdommer
BR0315296A (pt) Derivados do ciclohexanol espirocìclicos
EE200400020A (et) Asendatud oksasolidinoonid kombineeritud raviks
MXPA03006855A (es) Metodo para tratar insuficiencia cardiaca cronica y/o niveles elevados de colesterol, utilizando acido 3,5-diyodotiropropionico, y metodo para su preparacion.
DK0841949T3 (da) Anvendelse af saccharid-konjugater
BR0308904A (pt) Método de tratamento de gastroparesia, e, uso de um composto de glp-1
BR0206568A (pt) Novo método e composições para o tratamento local de doença de meniere, de zumbido no ouvido e/ou de perda de audição
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
PT998287E (pt) Utilizacao de levobupivacaina
BR0207316A (pt) Derivados de epotilona para o tratamento de tumores refratários
EE05515B1 (et) 1 2 diarlbensimidasoolid mikrogliia aktivatsiooniga seotud haiguste raviks
CY1108377T1 (el) Χρηση ενωσεων 1-φαινυλο-3-διμεθυλαμινο-προπανιου για τη θεραπεια της ακρατειας ουρων
BR9916190A (pt) Emprego de inibidores do canal kqt1 para a preparação de um medicamento para o tratamento de doenças, que são provocadas por helmintos e ectoparasitas
DK1368019T4 (da) Esmololformulering
DE59904180D1 (de) Cyclopentabenzofuran-derivate und ihre verwendung
TR200101245T2 (tr) N-arilsulfonil-aminoasit-omega-amidler
DE60128100D1 (de) Analgetisches arzneimittel
CY1119257T1 (el) Θεραπεια του νευροπαθητικου πονου με ανταγωνιστες υποδοχεα δεξτρομεθορφανης n-meθυλ-d-ασπαρτικων (nmda)
BR0013313A (pt) Derivados substituìdos de pirrolidino-2,3,4- triona-3-oxina eficazes como antagonistas de receptores de nmda

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties